Executive Management

Thomas Jensen

Chief Executive Officer, Founder

Thomas H. Jensen has been the Chief Executive Officer of Allarity Therapeutics, Inc. since December 2023, a director of ours since July 2022, and has been a part of the Company’s since its inception serving in a range of capacities. Before becoming the CEO, Mr. Jensen has been the Senior Vice President, Investor Relations since June 2022, and a director of ours since July 2022. Previously, Mr. Jensen served as Senior Vice President of information Technology of Allarity Therapeutics, Inc. as well as of our predecessor, Allarity Therapeutics A/S, since June 2020. Mr. Jensen previously served as the Chief Technology Officer of our predecessor from 2004 to June 2020. Mr. Jensen co-founded Allarity Therapeutics A/S in 2004. Mr. Jensen also established and currently leads our laboratories in Denmark. Alongside nurturing our global laboratories, Mr. Jensen is instrumental in building our investor relations operations, securing operational financing, and fostering the business growth of Allarity Therapeutics. Amongst Mr. Jensen’s accolades are his inventions of molecular biological guidelines combined with techniques for high quality reproducible RNA extraction and downstream processing. This allows for high resolution analysis of cancer patients’ biopsies. Mr. Jensen’s inventions are an important foundation of the DRP® -Drug Response Prediction platform. Mr. Jensen also currently serves on the Board of Cardeon AB, a Swedish company that invests in innovative Nordic companies and start-ups in medical technology and Life Science. Mr. Jensen holds a Bachelor of Science degree in Biology from the Technical University of Denmark, and conducted further studies in Biology at the University of Copenhagen.

Jeremy R. Graff, Ph.D.

President and Chief Development Officer

Jeremy R. Graff, Ph.D., has served as President and Chief Development Officer at Allarity Therapeutics since October 2024, following his role as Executive Advisor to the Company since December 2023. He brings over two decades of experience in the biotech and pharmaceutical industry, with a proven track record in the development of targeted cancer therapies from the earliest target discovery activities all the way through phase 3 clinical development. During his tenure as Executive Advisor, Dr. Graff provided strategic guidance for the Company’s clinical programs and business directives, helping to re-shape Allarity’s development efforts.

During his nearly 17-year tenure at Eli Lilly and Company, Dr. Graff established and led the translational oncology group, responsible for enabling the 31 clinical assets in Eli Lilly’s oncology portfolio. His work has resulted in numerous patents and more than 60 publications, which have collectively garnered over 22,000 research citations. Dr. Graff also serves as a member of the Board of Directors of IN8bio, Inc., a member of the Board of Trustees for the Wood Hudson Cancer Research Laboratory, and is on the Scientific Advisory Board of Avicenna Biosciences, Inc.

Dr. Graff completed a post-doctoral fellowship at the Johns Hopkins University School of Medicine. In his role at Allarity, he continues to drive the Company’s clinical development programs and to shape the strategic direction of the Company.

Jeff Ervin

Chief Financial Officer

Mr. Ervin has served as Chief Financial Officer of Allarity Therapeutics since July, 2025.  He has more than 20 years of experience in senior corporate and financial roles across the healthcare industry.

Recently, Mr. Ervin was the Chairman and Chief Executive Officer of IMAC Holdings (Nasdaq: BACK), where he successfully launched the corporation, executed its IPO, guided a clinical trial for Parkinson’s disease and expanded the retail medical business to over 30 locations in seven states.  He also served as co-Chief Financial Officer of DDC Enterprises (NYSE: DDC) delivering capital market engagement, asset optimization and integration, and U.S. based financial reporting.  Jeff currently serves as an independent board member of Cingulate, Inc. (Nasdaq: CING). 

Mr. Ervin received his M.B.A from Vanderbilt University and his B.S. in finance from Miami University.

Steen Knudsen, Ph.D.

Chief Scientific Officer, Founder

Steen Knudsen has been the Chief Scientific Officer of our predecessor since 2006 and continues to be our Chief Scientific Officer. Dr. Knudsen is a co-founder of Allarity Therapeutics A/S and the inventor of DRP®, the Drug Response Prediction Platform, which is our core technology and companion diagnostics platform.
 
Dr. Knudsen is also a former Professor of Systems Biology with extensive expertise in mathematics, bioinformatics, biotechnology, and systems biology. He co-founded our predecessor in 2004 and served as its CEO from 2004 to 2006. Dr. Knudsen also previously served as a member on our predecessor’s Board of Directors from 2016 to 2020. In addition, Dr. Knudsen also currently serves as the Chief Executive Officer of MPI, Inc., our operating subsidiary in the U.S.
 
Dr. Knudsen holds an M.Sc. degree in Engineering from the Technical University of Denmark and a Ph.D. degree in Microbiology from the University of Copenhagen. He received Postdoctoral training in computational biology from Harvard Medical School.

Quick Links

SEC Filings

IR Contact

[email protected]

Investor Email Alerts